CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma

[1]  Ga-Young Park,et al.  Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer , 2023, Scientific reports.

[2]  I. Nakagawa,et al.  Natural Killer Cell-Based Immunotherapy against Glioblastoma , 2023, International journal of molecular sciences.

[3]  I. Nakagawa,et al.  Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors , 2022, Regenerative therapy.

[4]  T. Todo,et al.  Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial , 2022, Nature Medicine.

[5]  D. Olive,et al.  Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity , 2021, Journal for ImmunoTherapy of Cancer.

[6]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[7]  I. Nakagawa,et al.  CRISPR-Cas9–Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells , 2021, International journal of molecular sciences.

[8]  N. Huntington,et al.  Drug target validation in primary human natural killer cells using CRISPR RNP , 2020, Journal of leukocyte biology.

[9]  Jeffrey S. Miller,et al.  Exploring the NK cell platform for cancer immunotherapy , 2020, Nature Reviews Clinical Oncology.

[10]  Matthew S. McNeill,et al.  Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. , 2020, Blood.

[11]  K. Kakimi,et al.  A novel scoring method based on RNA‐Seq immunograms describing individual cancer‐immunity interactions , 2020, Cancer science.

[12]  Gregory F. Wu,et al.  cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity , 2020, Nature.

[13]  Eric W. Sankey,et al.  Immune suppression in gliomas , 2020, Journal of Neuro-Oncology.

[14]  D. Kaufman,et al.  Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. , 2020, Cell stem cell.

[15]  C. Brennan,et al.  Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells , 2020, Cell.

[16]  M. Weller,et al.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.

[17]  I. Nakagawa,et al.  Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth , 2020, Cells.

[18]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[19]  R. Auer,et al.  Killers 2.0: NK cell therapies at the forefront of cancer control. , 2019, The Journal of clinical investigation.

[20]  D. Finlay,et al.  Immunometabolism and natural killer cell responses , 2019, Nature Reviews Immunology.

[21]  I. Nakagawa,et al.  Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro , 2019, PloS one.

[22]  L. Lanier,et al.  Natural Killer Cells in Cancer Immunotherapy , 2019, Annual Review of Cancer Biology.

[23]  S. Beyaz,et al.  Metabolic reprogramming of natural killer cells in obesity limits antitumor responses , 2018, Nature Immunology.

[24]  G. Linette,et al.  CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges , 2018, Neuro-oncology.

[25]  Walker S. Lahr,et al.  A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy , 2018, bioRxiv.

[26]  J. Barnholtz-Sloan,et al.  Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014 , 2018, JAMA oncology.

[27]  Xiaohu Zheng,et al.  Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression. , 2018, Cell metabolism.

[28]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[29]  E. Sahai,et al.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.

[30]  F. Lieberman,et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.

[31]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[32]  S. Mattarollo,et al.  Natural killer cell metabolism. , 2017, Molecular immunology.

[33]  Jaeho Bae,et al.  Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody , 2017, Scientific Reports.

[34]  Kecheng Xu,et al.  Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer , 2017, OncoTargets and therapy.

[35]  F. Claas,et al.  Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia , 2016, Science Translational Medicine.

[36]  R. Kiessling,et al.  IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. , 2016, Blood.

[37]  Laura F. Dagley,et al.  CIS is a potent checkpoint in NK cell–mediated tumor immunity , 2016, Nature Immunology.

[38]  Y. Naito,et al.  Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer , 2015, Journal of Translational Medicine.

[39]  David L Porter,et al.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.

[40]  Garth L. Warnock,et al.  Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA) , 2015, Cytotechnology.

[41]  M. Cooper,et al.  Activation-Specific Metabolic Requirements for NK Cell IFN-γ Production , 2015, The Journal of Immunology.

[42]  David K. Finlay,et al.  mTORC1-Dependent Metabolic Reprogramming Is a Prerequisite for NK Cell Effector Function , 2014, The Journal of Immunology.

[43]  E. Gilson,et al.  The metabolic checkpoint kinase mTOR is essential for interleukin-15 signaling during NK cell development and activation , 2014, Nature Immunology.

[44]  Chih-Hao Chang,et al.  Fueling Immunity: Insights into Metabolism and Lymphocyte Function , 2013, Science.

[45]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[46]  W. Xiao,et al.  Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells. , 2012, International immunopharmacology.

[47]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[48]  S. Rosenberg,et al.  Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression , 2011, Clinical Cancer Research.

[49]  Randal J. Kaufman,et al.  From endoplasmic-reticulum stress to the inflammatory response , 2008, Nature.

[50]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[51]  Lewis L Lanier,et al.  Up on the tightrope: natural killer cell activation and inhibition , 2008, Nature Immunology.

[52]  Yuetsu Tanaka,et al.  Potential role of natural killer cells in controlling growth and infiltration of AIDS‐associated primary effusion lymphoma cells , 2006, Cancer science.

[53]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[54]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[55]  R. Kaufman,et al.  ER stress and the unfolded protein response. , 2005, Mutation research.

[56]  C. Gross,et al.  Treatment of Colon and Lung Cancer Patients with ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells , 2004, Clinical Cancer Research.

[57]  H. Harada,et al.  Autologous natural killer cell therapy for human recurrent malignant glioma. , 2004, Anticancer research.

[58]  D. Ron,et al.  Translational control in the endoplasmic reticulum stress response. , 2002, The Journal of clinical investigation.

[59]  R. Kaufman.  Orchestrating the unfolded protein response in health and disease. , 2002, The Journal of clinical investigation.

[60]  M. Schapira,et al.  Regulated translation initiation controls stress-induced gene expression in mammalian cells. , 2000, Molecular cell.

[61]  Eric D. Spear,et al.  The Unfolded Protein Response Regulates Multiple Aspects of Secretory and Membrane Protein Biogenesis and Endoplasmic Reticulum Quality Control , 2000, The Journal of cell biology.

[62]  Mingqing Li,et al.  ATF6 as a Transcription Activator of the Endoplasmic Reticulum Stress Element: Thapsigargin Stress-Induced Changes and Synergistic Interactions with NF-Y and YY1 , 2000, Molecular and Cellular Biology.

[63]  Peter Walter,et al.  Functional and Genomic Analyses Reveal an Essential Coordination between the Unfolded Protein Response and ER-Associated Degradation , 2000, Cell.

[64]  Hiderou Yoshida,et al.  Identification of the cis-Acting Endoplasmic Reticulum Stress Response Element Responsible for Transcriptional Induction of Mammalian Glucose-regulated Proteins , 1998, The Journal of Biological Chemistry.

[65]  E. Oldfield,et al.  Intratumoral LAK cell and interleukin-2 therapy of human gliomas. , 1989, Journal of neurosurgery.

[66]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[67]  R. Verhaak,et al.  GlioVis data portal for visualization and analysis of brain tumor expression datasets. , 2017, Neuro-oncology.

[68]  L. Downs,et al.  A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. , 2011, Cytotherapy.

[69]  R. Kaufman,et al.  A trip to the ER: coping with stress. , 2004, Trends in cell biology.

[70]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..